✉news HealthMedicine first seen 10 h ago, last 54 min ago, peak #6

Laverock Therapeutics expands into in vivo CAR-T and genetic medicine

Original: Cell Therapy Weekly: Laverock Therapeutics Expands to In Vivo CAR-T and Genetic Medicine

UK-based biotech Laverock Therapeutics has announced an expansion of its work into in vivo CAR-T cell therapy and broader genetic medicine, moving beyond ex vivo approaches. The update, featured in Cell Therapy Weekly, drew attention from the cell and gene therapy community, where in vivo CAR-T is seen as a promising next step for making cell therapies simpler and more scalable.

Why now: The company's strategic expansion into a fast-moving area of cell therapy research is news for the biotech and regenerative medicine sector.

Laverock TherapeuticsRegMedNet

Open on news →

Rank over time, top of the chart is #1. 8 snapshots from 10 h ago to 54 min ago.

Evidence

• Cell Therapy Weekly: Laverock Therapeutics Expands to In Vivo CAR-T and Genetic Medicine · RegMedNet

API: https://socialmediatrends-api.osmike.com/v1/trends/672590